Study S001136

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT00849056
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 310
Start: 2009-01
Primary completion: 2011-11
Lead sponsor: GlaxoSmithKline
Conditions: Diabetes Mellitus, Type 2
Interventions: BIOLOGICAL:albiglutide; DRUG:placebo
Results posted: TRUE
Individual participant data sharing: YES

Registered primary outcomes

Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52 [Baseline and Week 52]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0048818	Management of type 2 diabetes in renal disease—the twilight of the gods Bettina Johanna Kraus, Nephrology Dialysis Transplantation	2018	Other trial	DOI	cites ClinicalTrials.gov:NCT00849056
R0014141	Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. Home PD, Diabetes research and clinical practice	2017	Randomized trial	PMID 28683300 DOI	cites ClinicalTrials.gov:NCT00849056; registry reference DERIVED:28683300